We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Humanigen has executed a licensing agreement with Telcon RF Pharmaceutical and KPM Tech for development and commercialisation rights of its Covid-19 drug lenzilumab for South Korea and the Philippines.